Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.69 |
| ▸ | BRD2 | P25440 | 8/20 | 0.69 |
| ▸ | BRD3 | Q15059 | 8/20 | 0.69 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TAF1 | P21675 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | EP300 | Q09472 | 1/20 | 0.68 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.68 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.68 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.68 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.68 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836774 | 1.00 | BRD4 (0.69) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL5836786 | 1.00 | BRD4 (0.69) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL5837533 | 0.94 | BRD4 (0.75) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL5837528 | 0.94 | BRD4 (0.75) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL13178509 | 0.93 | BRD4 (0.71) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL24630418 | 0.91 | BRD4 (0.81) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL25698792 | 0.91 | BRD4 (0.81) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL17503201 | 0.91 | BRD4 (0.74) | BRD4BRD2BRD3 | |
| SCHEMBL17503199 | 0.91 | BRD4 (0.74) | BRD4BRD2BRD3 | |
| SCHEMBL17503200 | 0.91 | BRD4 (0.74) | BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030246-B2 | Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20040132724-A1 | Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132724-A1 | Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof | STAT6, HRH4, HRH1 | BRD4 39/4885BRD2 153/4885BRD3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.